MARIE SKODOWSKACURIE ACTIONS Innovative Training Networks H 2020

MARIE SKŁODOWSKA-CURIE ACTIONS Innovative Training Networks : H 2020 “MEDICIS-produced radioisotope beams for medicine”

New hope for cancer patients 152 Tb-NOGADA-NT e+ e 149 Tb-NOGADA-NT 2 x p+ 2 x n° Highly ionizing particle and low penetration depth

From 2015 CERN-MEDICIS will be the first worldwide facility dedicated to mass-separated radioisotope beams for medical applications. Its network, consisting of university hospitals, hadron therapy centers and isotope distribution entrepreneurial companies across France, Italy and Switzerland, is leading the field of oncological research, imaging and personalized treatments. It will act as the seed for the extended MEDICIS-PROMED network and train a new generation of entrepreneurial scientists to develop systems for new personalized treatments throughout Europe.

Lead Participant Short Name End month ESRs involve ment 1 Mass separation of innovative medical isotopes using CERNMEDICIS Research 3 JOGU 4 48 2, 4, 5, 7, 10 2 11 Carbon PET-aided hadron therapy Research 6 CNAO 4 48 3, 9, 11 + CH 1, 4 3 Theranostic radiopharmaceuticals for imaging/treatment of ovarian Research cancers 4 AAA 4 48 1, 6, 8 + CH 2, 33 4 Training 1 CERN 4 48 1 -11 +CH 1 -43 5 Management 1 CERN 1 48 N/A 6 Communication 5 C 2 TN 6 48 1 -11 +CH 1 -43 WP No Work Package Title Activity Type Start Month Lead Participant No Work Package List

List of scientific trainings Training Knowledge gained Mass separators isotope mass separation isotope production targets and ion sources Hands-on training Materials and radiation 2 D materials Graphene Material performance and degradation Multiple particle tracking code Radiation protection Hadron therapy treatment planning Shielding and operational safety Fluka Monte-Carlo Code Institution WP 1, 2 Materials for demanding environments 1, 2 New CDT school/ Univ. Manchester INFN, CERN 1, 2, 3 Isolde, CERN Radiobiology Biological radiation dose-response curve DNA damage and repair Univ. Pavia, CNAO 2, 3 High power Lasers Laser spectroscopy Atomic transitions Laser ionization JOGU 1, 3 5 f intermetallic phase diagram Inorganic synthesis of intermetallic alloys Handling of actinide materials Characterization techniques C 2 TN-IST 1 Molecular oncology Molecular biology of normal and cancer cells Hallmarks of cancer Development of anti-cancer drugs EPFL-ISREC 2, 3 Radiopharmaceuticals synthesis Solid phase peptide synthesis principles Chelators for radiometals Automated modules C 2 TN-IST 2, 3 Radioisotope production Production cross-sections Energy deposition Isotope separation and target reprocessing ARRONAX 1, 2 Nuclear spectroscopy Properties of exotic nuclei Optical techniques Combining atomic traps and lasers KUL 1, 2, 3 Ionization in plasma Classification of plasmas Atomic phenomena Experimental characterization EPFL 1 Robotics and automation Process definition Programed vs remote controlled Practical cases EPFL 1, 2, 3 CERN Accelerator School Basic physics of accelerators Accelerator components Practical cases CERN 1, 2, 3 Nuclear engineering Basics of materials for nuclear environments Radiation damage Heat power dissipation Univ. Manchester 1, 2 HUG/CHUV 2, 3 Functional imaging Principle of PET-SPECT imaging Image treatment softwares

Time table Outreach Man’ gmt Training therano 11 C had Isotope stic therapy separ Months 1 2 Phase ESR 2 CERN ESR 4 Graphne inst. ESR 5 JOGU ESR 7 C 2 TN ESR 10 PAX ESR 3 CERN ESR 9 CNAO ESR 11 KUL ESR CH 1 HUG ESR CH 4 EPFL ESR 1 CERN ESR 6 AAA ESR 8 C 2 TN ESR CH 2 CHUV ESR CH 3 HUG Secondments Training events Worsksh/sum_schl Entrepreneurship Doctoral training Visiting Scientists Conference Annual appraisal Recruitment Mid-term review Meetings 3 4 1 st phase: familiarization 5 6 7 8 9 Student Visits Prize, contest Website Public Lecture, Conf 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 K KW S GT V S S 1 S S 2 nd phase: exploration S S M S S M S S S M M S S S S M S S W V V M S M ST V S S S WS PL M D S M D M S S S C 1 S S MT 2 3 rd phase : Implementation M S S S S D S S M S S S D S S D S S S D S 1 V P S S S 4 th phase : Conclusion & Extrapolation D D S S S D S S S D S S D S 2 V C 2 3 P C E P Con